Medical Devices & Bioproduction Equipment - Cell and Gene Therapy
Strategic Profile
BioLife specializes in biopreservation and cold chain workflow solutions, developing proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. Flagship offerings include CryoStor cryopreservation media, HypoThermosol hypothermic storage solution, and the ThawSTAR automated cell thawing instrument.
Cyborg Score Rationale
BioLife operates in a high-growth market with proprietary products addressing critical infrastructure gaps in cell and gene therapy. Strong analyst coverage and recent EPS estimate increases signal confidence, though pre-profitability and earnings volatility warrant moderate caution.
Top Insights
Analysts at Northland Securities raised FY2026 earnings per share estimates in February 2026, signaling improved confidence in trajectory
Market cap of $1.17 billion with beta of 1.90, indicating higher volatility than broader market
Trailing EPS of -$0.38, showing company remains unprofitable despite growth
Covered by 20 analysts, indicating institutional interest in the cell and gene therapy space
Named Competitors
Cell Processing Solutions — Cryopreservation and cell processing equipment
Regenerative Medicine Infrastructure — Cold storage and logistics solutions
Biopreservation Media — Competing cryopreservation formulations